Dyne Therapeutics Inc. Common Stock vs Hasbro, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Hasbro, Inc. trades at $96.15 (market cap $13.53B). The key difference: Hasbro, Inc. is far larger — about 4.7× Dyne Therapeutics Inc. Common Stock's market cap, and Hasbro, Inc. pays a 2.92% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Hasbro, Inc. for 97 Days on average.
| DYN | HAS | |
|---|---|---|
Market Cap | $2.86B | $13.53B |
Volume | 3,341,579 | 1,762,034 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $105.88 |
52-Week Low | $14.60 | $74.13 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $2.18B | $15.72B |
Dividend Yield | — | 2.92% |
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Hasbro (HAS) trades at $95.46, up 0.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings beats in recent quarters (Q4 2025-Q2 2026) and positive cash flow trends, though 2025 net income was negative. Valuation metrics include a P/E of 17.07 and P/S of 2.74, while institutional interest remains high with recent purchases by HSBC and Virginia Retirement Systems.
Outlook is positive with a consensus price target of $107.60 (13% upside), supported by Magic: The Gathering growth and cost savings. Risks include high debt levels (debt-to-asset ratio of 59.09% in 2025) and sensitivity to consumer spending trends. The upcoming Q3 2026 earnings on October 20 will be a key catalyst.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →